Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials

Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in ... Read More